View Past PerformanceBiotechnology Assets 대차대조표 건전성재무 건전성 기준 점검 6/6Biotechnology Assets 의 총 주주 지분은 €7.0M 이고 총 부채는 €1.6M, 이는 부채 대 자기자본 비율을 23% 로 가져옵니다. 총자산과 총부채는 각각 €13.6M 및 €6.6M 입니다.핵심 정보23.02%부채/자본 비율€1.60m부채이자보상배율n/a현금€666.22k자본€6.96m총부채€6.60m총자산€13.56m최근 재무 건전성 업데이트분석 기사 • Dec 05We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Nov 14We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Apr 19Is Biotechnology Assets (BME:BST) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Nov 17Is ADL Bionatur Solutions (BME:ADL) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...모든 업데이트 보기Recent updatesReported Earnings • Jun 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.43m (up 16% from FY 2024). Net loss: €1.92m (loss narrowed 34% from FY 2024).공시 • Jun 01Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026. Location: gomez acebo & pombo abogados, paseo de la castellana 216, torre realia, madrid., SpainNew Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (€3.1m revenue, or US$3.5m). Market cap is less than US$100m (€17.4m market cap, or US$20.2m).New Risk • Jan 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (6.7% average weekly change). Minor Risks Revenue is less than US$5m (€3.1m revenue, or US$3.6m). Market cap is less than US$100m (€16.3m market cap, or US$19.5m).분석 기사 • Dec 05We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...공시 • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid SpainReported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.7m).New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.0% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.4m market cap, or US$24.3m).분석 기사 • Nov 14We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€23.1m market cap, or US$24.4m).New Risk • Oct 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.0m market cap, or US$20.6m).공시 • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid SpainNew Risk • Apr 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.8m market cap, or US$23.4m).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.5% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m).New Risk • Oct 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m).분석 기사 • Apr 19Is Biotechnology Assets (BME:BST) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Nov 17Is ADL Bionatur Solutions (BME:ADL) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.Is New 90 Day High Low • Feb 08New 90-day high: €0.84The company is up 69% from its price of €0.49 on 10 November 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 18New 90-day high: €0.67The company is up 64% from its price of €0.41 on 20 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.재무 상태 분석단기부채: BST 의 단기 자산 ( €4.6M )이 단기 부채( €3.3M ).장기 부채: BST의 단기 자산(€4.6M)이 장기 부채(€3.3M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: BST 의 순부채 대 자기자본 비율( 13.4% )은 satisfactory로 간주됩니다.부채 감소: BST의 부채 대비 자본 비율은 지난 5년 동안 195.3%에서 23%로 감소했습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: BST 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: BST 무료 현금 흐름이 역사적 비율인 36.6 로 계속 증가할 경우 1.4 년 동안 충분한 현금 활주로를 보유하고 있습니다. 36.6 % 매년.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/26 01:13종가2026/06/26 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biotechnology Assets, S.A.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Pooya HemamiEdison Investment ResearchIñigo Recio PascualGVC Gaesco Valores
분석 기사 • Dec 05We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Nov 14We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • Apr 19Is Biotechnology Assets (BME:BST) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Nov 17Is ADL Bionatur Solutions (BME:ADL) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Jun 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.43m (up 16% from FY 2024). Net loss: €1.92m (loss narrowed 34% from FY 2024).
공시 • Jun 01Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026. Location: gomez acebo & pombo abogados, paseo de la castellana 216, torre realia, madrid., Spain
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (€3.1m revenue, or US$3.5m). Market cap is less than US$100m (€17.4m market cap, or US$20.2m).
New Risk • Jan 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (6.7% average weekly change). Minor Risks Revenue is less than US$5m (€3.1m revenue, or US$3.6m). Market cap is less than US$100m (€16.3m market cap, or US$19.5m).
분석 기사 • Dec 05We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
공시 • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
Reported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.7m).
New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.0% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.4m market cap, or US$24.3m).
분석 기사 • Nov 14We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€23.1m market cap, or US$24.4m).
New Risk • Oct 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.0m market cap, or US$20.6m).
공시 • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
New Risk • Apr 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.8m market cap, or US$23.4m).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.5% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m).
New Risk • Oct 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m).
분석 기사 • Apr 19Is Biotechnology Assets (BME:BST) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Nov 17Is ADL Bionatur Solutions (BME:ADL) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.
Is New 90 Day High Low • Feb 08New 90-day high: €0.84The company is up 69% from its price of €0.49 on 10 November 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 18New 90-day high: €0.67The company is up 64% from its price of €0.41 on 20 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.